Ketamine as a novel treatment protocol for treatment-resistant major depressive disorder
Advances in Pharmacology and Therapeutics Journal · 2022
DOI: 10.18502/aptj.v1i2.8674 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Advances in Pharmacology and Therapeutics Journal, 2022. Verfasst von Atena Fallah Tafti und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Aims
Major depressive disorder (MDD) has devastating effects on patient's quality of life (QOL). It seems that the use of ketamine in the treatment of MDD is an easy and less invasive technique compared with invasive methods, such as electroconvulsive therapy (ECT). As there were few studies in this regard, especially in Yazd province, the current study aimed to evaluate the therapeutic effect of repeated injected ketamine on patients with MDD and resistant to treatment.
Methods
This hospital-based open-label prospective study was conducted from September 2017 to May 2019 at Comprehensive Psychiatric Center, Taft,Yazd, Iran. In this pre-and post- trial, 18 patients with a diagnosis of MDD were recruited. The patients were diagnosed with MDD based on Diagnostic and Statistical Manual of Mental Disorders (5e) text revision Adapted from American Psychiatric Association (DSM 5). The patients aged between 18 to 70 years. Patients were eligible to participate in this study if they did not have history of physical or mental comorbidity. After completing Hamilton Depression Rating Scale (HDRS), the patients received 0.5 mg/kg ketamine infusion over 40 minutes with vital signs monitoring. After 2.5 hours of infusion, the HDRS was re-completed. The patients, who responded to treatment (≥50% reduction in HDRS score), received the treatment on days 3, 5, 7, 9, and 11 after the start of the study. Patients were re-evaluated after receiving the last dose of ketamine.
Results
After the first ketamine infusion, 13 of 18 (72%) patients responded to treatment. A significant decrease was seen between the mean depression score before (21.6 ± 8.5) and 2.5 hours after the first injection (9.7 ± 4.8) in responded patient (p
Zitieren
APA
Tafti, A. F., Yasini, S. M., Saghafi, F., Bidaki, R., Jafari, H., Vakili, M., & Rameshi, Y. (2022). Ketamine as a novel treatment protocol for treatment-resistant major depressive disorder. Advances in Pharmacology and Therapeutics Journal. https://doi.org/10.18502/aptj.v1i2.8674
Vancouver
Tafti AF, Yasini SM, Saghafi F, Bidaki R, Jafari H, Vakili M, et al. Ketamine as a novel treatment protocol for treatment-resistant major depressive disorder. Advances in Pharmacology and Therapeutics Journal. 2022. doi:10.18502/aptj.v1i2.8674
BibTeX
@article{Tafti2022,
author = {Tafti, Atena Fallah and Yasini, Seyed Mojtaba and Saghafi, Fatemeh and Bidaki, Reza and Jafari, Hossein and Vakili, Mahmoud and Rameshi, Yekta},
title = {Ketamine as a novel treatment protocol for treatment-resistant major depressive disorder},
journal = {Advances in Pharmacology and Therapeutics Journal},
year = {2022},
doi = {10.18502/aptj.v1i2.8674}
}
EUVIMED